United States Pharmaceuticals

CorMedix Inc (CRMD)

Track

CorMedix Inc. experienced multiple insider sales between November 2025 and January 2026. Directors and executives, including Janet Dillione, Alan Dunton, and Joseph Todisco, executed various sell transactions during this period. The most recent trading activity occurred on January 21, 2026. No insider buying activity has been reported in the provided data.
Ticker: CRMD Exchange: ASE
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for CorMedix Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 21 Jan 2026
Value US$4,862,141.37 | Price 400.92 | Shares 11,755 (+17.1%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-01-22 2026-01-21 S Sale
3.1
Dillione Janet
Non-Executive Director
11,755 +17.1%
400.92
US$4,862,141 		11,755 +17.1% 400.92 US$4,862,141
2026-01-21 2026-01-21 PrS Proposed sale
3.1
Janet Dillione

Director

Non-Executive Director
17,561
25.33
US$3,286,687 		17,561 25.33 US$3,286,687
2026-01-02 2025-12-30 S Sale
4.1
DUNTON ALAN W
Non-Executive Director
18,995 +9.5%
46.68
US$1,219,572 		18,995 +9.5% 46.68 US$1,219,572
2025-12-30 2025-12-30 PrS Proposed sale
4.1
Alan Dunton

Director

Non-Executive Director
20,000
12.97
US$259,400 		20,000 12.97 US$259,400
2025-12-19 2025-12-18 S Sale
3.9
Todisco Joseph

Chief Executive Officer

Executive Director
30,000 -5.6%
12.00
US$360,000 		30,000 -5.6% 12.00 US$360,000
2025-12-18 2025-12-18 PrS Proposed sale
3.9
Joseph Todisco

Officer

Officer
30,000
11.97
US$359,149 		30,000 11.97 US$359,149
2025-12-11 2025-12-09 S Sale
3.1
Dillione Janet
Non-Executive Director
34,000 -41.2%
12.00
US$408,000 		34,000 -41.2% 12.00 US$408,000
2025-12-10 2025-12-09 S Sale
3.5
Lefkowitz Steven W
Non-Executive Director
40,000 -33.2%
11.88
US$475,200 		40,000 -33.2% 11.88 US$475,200
2025-12-09 2025-12-09 PrS Proposed sale
3.5
Lefkowitz Steven W

Director

Non-Executive Director
40,000
11.26
US$450,400 		40,000 11.26 US$450,400
2025-12-09 2025-12-09 PrS Proposed sale
3.1
Janet Dillione

BOD
34,000
12.00
US$408,000 		34,000 12.00 US$408,000
2025-12-04 2025-12-02 S Sale
3.1
Dillione Janet
Non-Executive Director
46,657 -49.0%
10.00
US$466,570 		46,657 -49.0% 10.00 US$466,570
2025-11-26 2025-11-24 S Sale
3.1
Dillione Janet
Non-Executive Director
26,343 -35.2%
9.93
US$261,586 		26,343 -35.2% 9.93 US$261,586
2025-11-24 2025-11-24 PrS Proposed sale
3.1
Janet Dillione

Director

Non-Executive Director
73,000
9.97
US$727,927 		73,000 9.97 US$727,927
2025-11-18 2025-11-14 S Sale
3.1
Dillione Janet
Non-Executive Director
30,000 -38.2%
11.42
US$342,600 		30,000 -38.2% 11.42 US$342,600
2025-11-14 2025-11-14 PrS Proposed sale
3.1
Dillione Janet

Director

Non-Executive Director
30,000
10.94
US$328,200 		30,000 10.94 US$328,200
2025-11-10 2025-11-10 PrS Proposed sale
2.3
Erin Mistry

Former Officer

Officer
13,543
10.98
US$148,719 		13,543 10.98 US$148,719
2025-11-06 2025-11-06 PrS Proposed sale
2.3
Erin Mistry

Former Officer

Officer
13,908
10.97
US$152,503 		13,908 10.97 US$152,503
2025-10-27 2025-10-23 B Purchase
3.1
Kaplan Myron
Non-Executive Director
25,000 +14.2%
11.02
US$275,500 		25,000 +14.2% 11.02 US$275,500
2025-09-16 2025-09-12 S Sale
4.1
DUNTON ALAN W
Non-Executive Director
10,000 -19.9%
13.13
US$131,300 		10,000 -19.9% 13.13 US$131,300
2025-09-12 2025-09-12 PrS Proposed sale
4.1
DUNTON ALAN W

Director

Non-Executive Director
10,000
13.10
US$130,950 		10,000 13.10 US$130,950
2025-09-12 2025-09-12 PrS Proposed sale
3.9
Todisco Joseph

Officer

Officer
50,000
12.97
US$648,569 		50,000 12.97 US$648,569
2025-09-12 2025-09-12 S Sale
3.9
Todisco Joseph

Chief Executive Officer

Officer
50,000 -8.9%
13.00
US$650,000 		50,000 -8.9% 13.00 US$650,000
2025-09-11 2025-09-11 S Sale
3.5
Hurlburt Elizabeth

Chief Operating Officer

Officer
41,121 -18.9%
13.08
US$537,863 		41,121 -18.9% 13.08 US$537,863
2025-09-11 2025-09-09 S Sale
3.5
Hurlburt Elizabeth

Chief Operating Officer

Officer
12,876 -6.8%
13.51
US$173,955 		12,876 -6.8% 13.51 US$173,955
2025-09-11 2025-09-09 S Sale
3.2
Zelnick Kaufman Beth

Chief Legal Officer

Officer
400 -0.2%
12.82
US$5,128 		400 -0.2% 12.82 US$5,128
2025-09-11 2025-09-09 S Sale
3.2
Zelnick Kaufman Beth

Chief Legal Officer

Officer
49,600 -21.5%
13.41
US$665,136 		49,600 -21.5% 13.41 US$665,136
2025-09-09 2025-09-09 PrS Proposed sale
3.2
Zelnick Kaufman Beth

Officer

Officer
50,000
13.46
US$673,000 		50,000 13.46 US$673,000
2025-09-09 2025-09-09 PrS Proposed sale
3.5
Hurlburt Elizabeth

Officer

Officer
53,997
13.50
US$728,959 		53,997 13.50 US$728,959
2025-09-03 2025-09-03 PrS Proposed sale
3.3
David Matthew T

Former Officer

Officer
300,000
14.50
US$4,350,000 		300,000 14.50 US$4,350,000
2024-11-18 2024-11-14 S Sale
3.5
Hurlburt Elizabeth

EVP

Officer
140,027 -75.5%
11.18
US$1,565,670 		140,027 -75.5% 11.18 US$1,565,670
2024-11-14 2024-11-14 PrS Proposed sale
3.5
Hurlburt Elizabeth

Officer

Officer
140,027
11.12
US$1,556,416 		140,027 11.12 US$1,556,416
2024-12-13 2024-10-31 B Purchase
2.3
Mistry Erin

EVP, Chief Commercial Officer

Officer
1,500 +3.0%
9.99
US$14,985 		1,500 +3.0% 9.99 US$14,985
2024-03-14 2024-03-13 B Purchase
3.9
Todisco Joseph

Chief Executive Officer

Executive Director
13,561 +4.0%
3.74
US$50,718 		13,561 +4.0% 3.74 US$50,718
2023-12-18 2023-12-15 B Purchase
4.1
DUNTON ALAN W
Non-Executive Director
3,000 +24.5%
3.30
US$9,900 		3,000 +24.5% 3.30 US$9,900
2023-12-18 2023-12-14 B Purchase
4.1
DUNTON ALAN W
Non-Executive Director
3,000 +32.4%
3.45
US$10,350 		3,000 +32.4% 3.45 US$10,350
2023-11-21 2023-11-17 B Purchase
2.3
Mistry Erin

Chief Commercial Officer

Officer
1,000 +25.6%
4.00
US$4,000 		1,000 +25.6% 4.00 US$4,000
2023-09-08 2023-09-08 B Purchase
3.9
Todisco Joseph

Chief Executive Officer

Executive Director
10,000 +4.8%
3.71
US$37,100 		10,000 +4.8% 3.71 US$37,100
2023-05-19 2023-05-18 B Purchase
3.1
Kaplan Myron
Non-Executive Director
6,000 +3.7%
4.54
US$27,258 		6,000 +3.7% 4.54 US$27,258
2022-11-16 2022-11-15 B Purchase
3.9
Todisco Joseph

Chief Executive Officer

Executive Director
20,000 +9.0%
3.82
US$76,400 		20,000 +9.0% 3.82 US$76,400
2022-08-25 2022-08-24 B Purchase
3.9
Todisco Joseph

Chief Executive Officer

Executive Director
4,700 +2.2%
3.92
US$18,424 		4,700 +2.2% 3.92 US$18,424
2022-05-18 2022-05-17 B Purchase
3.1
Kaplan Myron
Non-Executive Director
5,000 +3.2%
3.78
US$18,900 		5,000 +3.2% 3.78 US$18,900
2022-05-17 2022-05-16 B Purchase
3.9
Todisco Joseph

Chief Executive Officer

Executive Director
10,000 +4.8%
3.38
US$33,800 		10,000 +4.8% 3.38 US$33,800
2021-12-07 2021-12-06 B Purchase
3.3
David Matthew T

Interim CEO and CFO

Officer
1,000 +46.5%
4.50
US$4,500 		1,000 +46.5% 4.50 US$4,500
2021-12-07 2021-12-06 B Purchase
3.3
David Matthew T

Interim CEO and CFO

Officer
1,000 +46.5%
4.50
US$4,500 		1,000 +46.5% 4.50 US$4,500
2021-11-19 2021-11-17 B Purchase
3.3
David Matthew T

Interim CEO and CFO

Officer
1,000 +87.0%
5.07
US$5,070 		1,000 +87.0% 5.07 US$5,070
2021-11-19 2021-11-16 B Purchase
3.1
Kaplan Myron
Non-Executive Director
10,000 +6.1%
5.14
US$51,400 		10,000 +6.1% 5.14 US$51,400
2021-05-25 2021-05-21 S Sale
3.5
Masson-Hurlburt Elizabeth

EVP, Head of Clinical Ops

Officer
8,000 -100.0%
6.92
US$55,394 		8,000 -100.0% 6.92 US$55,394
2020-09-09 2020-09-04 B Purchase
3.5
Lefkowitz Steven W
Non-Executive Director
2,215 +3.8%
3.98
US$8,816 		2,215 +3.8% 3.98 US$8,816
2020-09-09 2020-09-04 B Purchase
3.5
Lefkowitz Steven W
Non-Executive Director
3,500 +6.4%
4.00
US$14,000 		3,500 +6.4% 4.00 US$14,000
2020-09-08 2020-09-03 B Purchase
3.3
David Matthew T

Chief Financial Officer

Officer
1,150 +inf%
4.07
US$4,680 		1,150 +inf% 4.07 US$4,680
2020-09-04 2020-09-02 B Purchase
3.1
Kaplan Myron
Non-Executive Director
15,300 +11.4%
4.27
US$65,359 		15,300 +11.4% 4.27 US$65,359
2020-08-20 2020-08-19 B Purchase
2.7
Khan Mehmood
Non-Executive Director
8,433 +5.0%
4.90
US$41,296 		8,433 +5.0% 4.90 US$41,296
2020-08-20 2020-08-19 B Purchase
2.7
Khan Mehmood
Non-Executive Director
9,404 +5.8%
4.91
US$46,176 		9,404 +5.8% 4.91 US$46,176
2020-08-20 2020-08-18 B Purchase
2.7
Khan Mehmood
Non-Executive Director
21,082 +15.1%
4.86
US$102,366 		21,082 +15.1% 4.86 US$102,366
2020-08-20 2020-08-18 B Purchase
2.7
Khan Mehmood
Non-Executive Director
4,500 +3.3%
4.62
US$20,790 		4,500 +3.3% 4.62 US$20,790
2020-08-20 2020-08-18 B Purchase
2.7
Khan Mehmood
Non-Executive Director
2,331 +1.8%
4.60
US$10,723 		2,331 +1.8% 4.60 US$10,723
2020-08-17 2020-08-14 B Purchase
3.6
ARMSTRONG JR. JOHN L.

Exec VP of Tech Operations

Officer
10,000 +11.5%
4.35
US$43,460 		10,000 +11.5% 4.35 US$43,460
2020-08-17 2020-08-14 B Purchase
3.6
ARMSTRONG JR. JOHN L.

Exec VP of Tech Operations

Officer
7,500 +9.4%
4.14
US$31,050 		7,500 +9.4% 4.14 US$31,050
2020-08-17 2020-08-14 B Purchase
3.6
ARMSTRONG JR. JOHN L.

Exec VP of Tech Operations

Officer
10,000 +14.4%
4.16
US$41,600 		10,000 +14.4% 4.16 US$41,600
2020-08-17 2020-08-13 B Purchase
2.2
Baluch Khoso

Chief Executive Officer

Executive Director
4,830 +8.6%
4.14
US$19,985 		4,830 +8.6% 4.14 US$19,985
2020-08-17 2020-08-13 B Purchase
3.5
Mounts Phoebe

General Counsel

Officer
2,525 +54.0%
4.03
US$10,176 		2,525 +54.0% 4.03 US$10,176
2020-08-17 2020-08-13 B Purchase
3.1
Kaplan Myron
Non-Executive Director
15,000 +12.5%
4.08
US$61,160 		15,000 +12.5% 4.08 US$61,160
2020-08-14 2020-08-12 B Purchase
4.1
DUNTON ALAN W
Non-Executive Director
5,000 +400.0%
3.95
US$19,750 		5,000 +400.0% 3.95 US$19,750
2020-05-18 2020-05-15 B Purchase
3.1
Kaplan Myron
Non-Executive Director
10,000 +9.1%
3.85
US$38,500 		10,000 +9.1% 3.85 US$38,500
2020-03-19 2020-03-18 B Purchase
3.5
Mounts Phoebe

General Counsel
3,250 +228.1%
3.05
US$9,912 		3,250 +228.1% 3.05 US$9,912
2020-03-18 2020-03-18 B Purchase
2.2
Baluch Khoso

Chief Executive Officer
3,500 +6.7%
2.61
US$9,135 		3,500 +6.7% 2.61 US$9,135
2020-01-02 2019-12-30 B Purchase
3.5
Mounts Phoebe

General Counsel
1,425 +inf%
7.04
US$10,038 		1,425 +inf% 7.04 US$10,038
2019-12-17 2019-12-13 B Purchase Khan Mehmood
17,000 +14.7%
6.58
US$111,925 		17,000 +14.7% 6.58 US$111,925
2019-10-01 2019-09-30 B Purchase
1.4
Cook Robert W.

Chief Financial Officer
1,000 +3.8%
6.88
US$6,879 		1,000 +3.8% 6.88 US$6,879
2019-10-01 2019-09-30 B Purchase
3.1
Kaplan Myron
5,000 +4.8%
6.81
US$34,050 		5,000 +4.8% 6.81 US$34,050
2019-10-01 2019-09-27 B Purchase
3.5
Lefkowitz Steven W
5,000 +9.9%
6.75
US$33,750 		5,000 +9.9% 6.75 US$33,750
2019-08-19 2019-08-16 B Purchase Cook Robert W.

Chief Financial Officer
1,000 +3.9%
8.18
US$8,180 		1,000 +3.9% 8.18 US$8,180
2019-08-19 2019-08-16 B Purchase Cook Robert W.

Chief Financial Officer
1,000 +3.9%
8.18
US$8,180 		1,000 +3.9% 8.18 US$8,180
2019-08-16 2019-08-16 B Purchase Dillione Janet Non-Executive Director
6,147 +13.0%
8.19
US$50,344 		6,147 +13.0% 8.19 US$50,344
2019-08-16 2019-08-16 B Purchase Kaplan Myron Non-Executive Director
6,000 +6.1%
8.06
US$48,360 		6,000 +6.1% 8.06 US$48,360
Explore more

More insider trading research around CorMedix Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America